Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: A toxicity analysis

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 2, 2010, Pages 144-147

  Birnbaum, Ariel ^a   Dipetrillo, Thomas ^a   Rathore, Ritesh ^a   Anderson, Elliott ^a   Wanebo, Harry ^a   Puthwala, Yacoub ^a   Joyce, Donald ^a   Safran, Howard ^a   Henderson, Denise ^a   Kennedy, Theresa ^a   Ready, Neal ^a   Sio, Terence Tai Weng ^a  

^a Brown University Oncology Group   (United States)

Author keywords

Cetuximab; Head and neck cancer; Radiation

Indexed keywords

CARBOPLATIN; CETUXIMAB; PACLITAXEL;

ACNE; ADULT; AGED; ANEMIA; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ESOPHAGUS ULCER; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OROPHARYNGEAL PAIN; PAIN; PHASE 2 CLINICAL TRIAL; RADIATION DERMATITIS; RADIATION DOSE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; WEIGHT REDUCTION; XEROSTOMIA;

ACNEIFORM ERUPTIONS; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUCOSITIS; NEOPLASM STAGING; PACLITAXEL; PROSPECTIVE STUDIES; RADIODERMATITIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77951044355     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181979093     Document Type: Article

References (20)

1. Al-Sarraf M, Leblanc M, Shanker PG, et al. Chemoradiotherapy versus radiation in patients with advanced nasopharyngeal cancer. Phase III randomized intergroup study 0099. J Clin Oncol. 1988;16:1310-1317.
2. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;34:2091-2098.
3. Brizel DM, Albers ME, Fishers R, et al. Hyperfractinated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1978-11804
4. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000;18:1458-1464.
5. Fan Z, Masui H, Altas I, et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53:4322-4328.
6. Fan Z, Lu Y, Wu X, et al. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994;269:27595-27602.
7. Shin D, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptortargeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001;7:1204-1213.
8. Basel1ga J, Yrigo J, Bourhis J, et al. A phase II multicenter study of the anti-epidermal growth 00.23factor receptor (EGFR) monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metasatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2005;23:5568-5577.
9. Burtness B, Goldwasser MA, Flood W, et al. Phase III Randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 2005;23:8646-8654.
10. Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in ling cancer. Clin Cancer Res. 2005;11:795-805.
11. Huang SM, bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:1935-1940.
12. Kasid U, Pirollo K, Dritschilo A, et al. Oncogenic basis of radiation resistance. Adv Cancer Res. 1993;61:195-233.
13. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354: 567-578.
14. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24:1072-1078.
15. Chougule PB, Akhtar MS, Rathore R, et al. Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: long-term follow-up of Brown University Oncology Group Phase II Study (HN-53). Head Neck. 2008;30:289-296.
16. Wanebo H, Chougule N, Ready N, et al. Preoperative therapy with reduced dose paclitaxel, and Carboplatin and radiation achieves similar complete response rate to a high dose regimen, but with reduced toxicity. 2000;19. ASCO Annual Meeting. Abstract 1655.
17. Choy H, Akerley W, Glantz M, et al. Concurrent paclitaxel and radiation therapy for solid tumors. Cancer Control. 1996;3:310-318.
18. Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008;70:391-395.
19. Vermoken J, Mesia R, Vega E, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy-results of a randomized phase III (Extreme) study. Proc Am Soc Clin Oncol. 2007;25:16S.Abstract 6091.
20. Lee N, Chuang C, Quivey J, et al. Skin toxicity because of intensitymodulated radiotherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2002;53:630-637.